News
Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...
Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...
6d
MedPage Today on MSNPhysical Activity and Rehabilitation in Duchenne Muscular DystrophyDysfunctional dystrophin, the muscle protein affected in Duchenne, leads to an important choice for patients about how to ...
Otsuka subsidiary Taiho Pharmaceuticals earlier announced that the results of a Phase III, randomized, placebo-controlled, ...
Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the best up and coming stocks to invest in now. On June 26, Edgewise ...
In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, ...
Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down ...
Sarepta Therapeutics Inc. misled investors about the safety and prospects for one of its Duchenne muscular dystrophy ...
The FDA is assessing the need for “further regulatory action” on Sarepta's Duchenne muscular dystrophy gene therapy in the ...
The FDA said yesterday that it is investigating the deaths from liver failure of two non-ambulatory boys with Duchenne ...
Capricor's DMD therapy Deramiocel is under FDA Priority Review with no major issues flagged; PDUFA date set for August 31, ...
The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results